These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 11049795)
1. Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice. Hoesley CJ; Saag MS; Chatham A; Kilby JM Clin Infect Dis; 2000 Oct; 31(4):1095-7. PubMed ID: 11049795 [TBL] [Abstract][Full Text] [Related]
2. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016 [TBL] [Abstract][Full Text] [Related]
3. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889 [No Abstract] [Full Text] [Related]
4. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. Benson CA; Deeks SG; Brun SC; Gulick RM; Eron JJ; Kessler HA; Murphy RL; Hicks C; King M; Wheeler D; Feinberg J; Stryker R; Sax PE; Riddler S; Thompson M; Real K; Hsu A; Kempf D; Japour AJ; Sun E J Infect Dis; 2002 Mar; 185(5):599-607. PubMed ID: 11865416 [TBL] [Abstract][Full Text] [Related]
5. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386 [TBL] [Abstract][Full Text] [Related]
6. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038 [TBL] [Abstract][Full Text] [Related]
7. Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors. Yozviak JL; Doerfler RE; Woodward WC Clin Infect Dis; 2002 Feb; 34(4):547-50. PubMed ID: 11797185 [TBL] [Abstract][Full Text] [Related]
8. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A; Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966 [TBL] [Abstract][Full Text] [Related]
9. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V; J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257 [TBL] [Abstract][Full Text] [Related]
10. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B; Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176 [TBL] [Abstract][Full Text] [Related]
11. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404 [TBL] [Abstract][Full Text] [Related]
12. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903 [TBL] [Abstract][Full Text] [Related]
13. Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E. Lolekha R; Sirivichayakul S; Siangphoe U; Pancharoen C; Kaewchana S; Apateerapong W; Mahanontharit A; Chotpitayasunondh T; Ruxrungtham K; Phanuphak P; Ananworanich J Clin Infect Dis; 2005 Jan; 40(2):309-12. PubMed ID: 15655753 [TBL] [Abstract][Full Text] [Related]
14. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771 [TBL] [Abstract][Full Text] [Related]
16. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes. Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Van der Linden D; Hainaut M; Goetghebuer T; Haelterman E; Schmitz V; Maes P; Peltier A; Levy J Pediatr Infect Dis J; 2007 Apr; 26(4):359-61. PubMed ID: 17414406 [TBL] [Abstract][Full Text] [Related]
18. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. Whitcomb JM; Parkin NT; Chappey C; Hellmann NS; Petropoulos CJ J Infect Dis; 2003 Oct; 188(7):992-1000. PubMed ID: 14513419 [TBL] [Abstract][Full Text] [Related]
19. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study. Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668 [No Abstract] [Full Text] [Related]
20. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. Call SA; Saag MS; Westfall AO; Raper JL; Pham SV; Tolson JM; Hellmann NS; Cloud GA; Johnson VA J Infect Dis; 2001 Feb; 183(3):401-8. PubMed ID: 11133371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]